An increased awareness of prostate cancer has led to a rise in the detection of this disease at a clinically localized stage at presentation. This article discusses the role of neoadjuvant hormonal ablation at this earlier stage to decrease tumor bulk and thus enhance survival.
Method
Outcomes from each primary modality for localized treatment of prostate cancer with and without neoadjuvant androgen deprivation (NAAD) are reviewed.
Results
Survival benefit using NAAD has not yet been demonstrated from prostatectomy. Long-term hormonal deprivation provides an improved time to progression and has decreased distant metastatic and biochemical failure for poor-risk patients undergoing external-beam radiation. The toxicities of brachytherapy can be decreased with NAAD.
Conclusions
NAAD with radical prostatectomy is considered to be investigational. The duration of NAAD needs to be delineated for poor-prognosis patients who are treated with external-beam radiation therapy, but the approach improves the local toxicity of brachytherapy.
References
1.
SmartC.R.. The results of prostate carcinoma screening in the US as reflected in the surveillance, epidemiology and end results program.Cancer.1997; 80: 1835–1844.
2.
SmithD.S., HumphreyP.A., CatalonaW.J.. The early detection of prostate carcinoma with prostate specific antigen: the Washington University experience.Cancer.1997; 80: 1852–1856.
3.
SohS., KattanM.W., BerkmanS.. Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy?J Urol.1997; 157: 2212–2218.
4.
FairW.R., HestonW.D.Is combined modality therapy appropriate for apparently localized carcinoma of the prostate?Urol Clin North Am.1991; 18: 477–480.
5.
FairW.R., AprikianA.G., CohenD.. Use of neoadjuvant androgen therapy in clinically localized prostate cancer.Clin Invest Med.1993; 6: 516–522.
6.
WalshD.C., JewellH.S.. Radical surgery for prostate cancer.Cancer.1980; 45(7 suppl): 1906–1911.
7.
FairW.R., CooksonM.S., StroumbakisN.. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results.Urology.1997; 49(3A suppl): 46–55.
8.
AprikianA.G., FairW.R., ReuterV.E.. Experience with neoadjuvant diethylstilbestrol and radical prostatectomy in patients with locally advanced prostate cancer.Br J Urol.1994; 74: 630–636.
9.
FairW.R., RabbaniF., BastarA.. Neoadjuvant hormone therapy before radical prostatectomy: update on the Memorial Sloan-Kettering Cancer Center trials.Mol Urol.1999; 3: 253–260.
10.
LabrieF., DupontA., CusanL.. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial.Clin Invest Med.1993; 16: 499–509.
11.
SolowayM.S., SharifiR., WajsmanZ.. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer: the Lupron Depot Neoadjuvant Prostate Cancer Study Group.J Urol.1995; 154: 424–428.
12.
SolowayM.S., SharifiR., WajsmanZ.. Randomized prospective study — radical prostatectomy alone vs radical prostatectomy preceded by androgen blockade in cT2b prostate cancer — initial results.Proc Am Urol Assoc.1996; 155(suppl): 976. Abstract.
13.
GoldenbergS.L., KlotzL., JewettM.. A randomized trial of neoadjuvant androgen withdrawal therapy prior to radical prostatectomy: 24 month post-treatment PSA results.J Urol.1997; 151(suppl): 357. Abstract.
14.
DalkinB.L., AhmannF.R., NagleR.. Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer.J Urol.1996; 155: 1357–1360.
15.
van der KwastT.H., TetuB., CandasB.. Prolonged neoadjuvant combined androgen blockade leads to a further reduction in prostatic tumor volume: three versus six months of endocrine therapy.Urology.1999; 53: 523–529.
16.
WhittingtonR., BroderickG.A., ArgerP.. The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate.Int J Radiat Oncol Biol Phys.1999; 44: 1107–1110.
17.
PoundC.R., PartinA.W., EisenbergerM.A.. Natural history of progression after PSA elevation following radical prostatectomy.JAMA.1999; 281: 1591–1597.
18.
MatsushimaH., GotoT., HosakaY.. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation.Cancer.1999; 85: 1822–1827.
19.
GleaveM.E., GoldenbergS.L., JonesE.C.. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.J Urol.1996; 155: 213–219.
20.
GleaveM.E., HsiehJ.T., WuH.C.. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.Cancer Res.1992; 52: 1598–1605.
21.
MillerJ.I., AhmannF.R., DrachG.W.. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer.J Urol.1992; 147: 956–961.
22.
GoldenbergS.L., BruchovskyN., GleaveM.E.. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report.Urology.1995; 45: 839–845.
23.
StameyT.A., KabalinJ.N., FerrariM.. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients.J Urol.1989; 141: 1088–1090.
24.
HanksG.E., HanlonA., SchultheissT.. Early prostate cancer: the national results of radiation treatment from the Patterns of Care and Radiation Therapy Group studies with prospects for improvement with conformal radiation and adjuvant androgen deprivation.J Urol.1994; 152: 1775–1780.
25.
FradetY.. The role of neoadjuvant androgen deprivation prior to radical prostatectomy.Urol Clin North Am.1996; 23: 575–585.
26.
OefeleinM.G.. Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration.J Urol.1998; 160: 1685–1688.
27.
HanksG.E., AsbellS., KrallJ.M.. Outcome for lymph node dissection negative T-1b, T-2(A-2,B) prostate cancer treated with external beam radiation therapy in RTOG 77-06.Int J Radiat Oncol Biol Phys.1991; 21: 1099–1103.
28.
BollaM., GonzalezD., WardeP.. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.N Engl J Med.1997; 337: 295–300.
29.
PilepichM.V., KrallJ.M., SauseW.T.. Prognostic factors in carcinoma of prostate: analysis of RTOG study 75-06.Int J Radiat Oncol Biol Phys.1989; 13: 339–349.
30.
PilepichM.V., CaplanR., ByhardtR.W.. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31.J Clin Oncol.1997; 15: 1013–1021.
31.
PilepichM.V., JohnM.J., KrallJ.M.. Phase II Radiation Therapy Oncology Group study of hormonal cytoreduction with flutamide and Zoladex in locally advanced carcinoma of the prostate treated with definitive radiotherapy.Am J Clin Oncol.1990; 13: 461–464.
32.
PilepichM.V., KrallJ.M., JohnM.J.. Hormonal cytoreduction in locally advanced carcinoma of the prostate treated with definitive radiotherapy: preliminary results of RTOG 83-07.Int J Radiat Oncol Biol Phys.1989; 16: 813–817.
33.
AkakuraK., BruchovskyN., GoldenbergS.L.. Effects of intermittent androgen suppression on androgen-dependent tumors: apoptosis and serum prostate-specific antigen.Cancer.1993; 71: 2782–2790.
34.
PilepichM.V., KrallJ.M., al-SarrafM.. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group.Urology.1995; 45: 616–623.
35.
HorwitzE.M., WinterK., HanksG.E.. Long-term outcome for patients with locally advanced non-metastatic prostate cancer treated with adjuvant hormones and radiation therapy versus radiation therapy alone: subset analysis of RTOG 85-31 and 86-10. Proceedings of the American Society of Therapeutic Radiology Oncology (ASTRO), San Antonio, Tex.Int J Radiat Oncol Biol Phys.1999; 45: 142. Abstract.
36.
PollackA.. Does radiotherapy add anything to androgen ablation?American Society of Clinical Oncology 2000 Educational Book.2000: 320–326.
37.
HanksG.E., LuJ., MachtayM.. RTOG Protocol 92-02: a phase III trial of the use of long term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate.Proc Annu Meet Am Soc Clin Oncol.2000; 19: 1284. Abstract.
38.
Radiation Therapy Oncology Group.A phase III trial of the study of endocrine therapy used as a cytoreductive and cytostatic agent prior to radiation therapy in good prognosis locally confined adenocarcinoma of the prostate. RTOG 94-08. January 8, 1999. http://www.rtog.org/summaries/.
39.
ZelefskyM.J., LyassO., FuksZ.. Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy.J Clin Oncol.1998; 16: 3380–3385.
40.
PottersL., TorreT., AshleyR.. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy.J Clin Oncol.2000; 18: 1187–1192.
41.
D'AmicoA.V., WhittingtonR., MalkowiczS.B.. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.JAMA.1998; 280: 969–974.
42.
GarnickM.B.. Hormonal therapy in the management of prostate cancer: from Huggins to the present.Urology.1997; 49(suppl 3A): 5–15.
43.
CooksonM.S., SoganiP.C., RussoP.. Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study.Br J Urol.1997; 79: 432–438.
